Εμφάνιση απλής εγγραφής

dc.creatorTsoucalas, G.en
dc.creatorKaramanou, M.en
dc.creatorVavuranakis, M.en
dc.creatorSgantzos, M.en
dc.creatorStefanadis, C.en
dc.creatorAndroutsos, G.en
dc.date.accessioned2015-11-23T10:52:18Z
dc.date.available2015-11-23T10:52:18Z
dc.date.issued2015
dc.identifier.issn1381-6128
dc.identifier.urihttp://hdl.handle.net/11615/34053
dc.description.abstractHypertension provoked since the beginning of the 19th century a medical debate between physicians. The early antihypertensive agents were poorly tolerated. Progress towards more effective drugs, appeared after the 2nd World War. Thiocyanates, dehydrogenated alkaloids of ergot, barbiturates, bismuth and bromides, were soon replaced by phenoxbenzamine, hexamethonium, pentolinium, and mecamylamine. Thiazide diuretics were the biggest breakthrough during the early 1960's. Then Beta(beta)-blockers and angiotensin-converting enzyme inhibitors heralded a new era, until 1995, when losartan, the first non-peptide anti-hypertensive drug, was introduced. The plethora of the antihypertensive drugs changed the relationship between physicians and patients, pushed medicine towards prevention, and altered the medical marketing forever.en
dc.source.uri<Go to ISI>://WOS:000349459600003
dc.subjectAntihypertensive drugsen
dc.subjectthiazide diureticsen
dc.subjectBeta(beta)-blockersen
dc.subjectangiotensin-converting enzyme inhibitorsen
dc.subjectlosartanen
dc.subjectphysician-patienten
dc.subjectrelationshipen
dc.subjectmedical marketingen
dc.subjectHYPERTENSIONen
dc.subjectCHLOROTHIAZIDEen
dc.subjectPROPRANOLOLen
dc.subjectBLACK,JAMESen
dc.subjectHISTORYen
dc.subjectPharmacology & Pharmacyen
dc.titleMilestones in Antihypertensive Drug Treatmenten
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής